IBSRELA
tenapanor Small Molecule Target: NHE3
- Irritable Bowel Syndrome with Constipation
- Chronic Idiopathic Constipation
Ardelyx
Most recent annual filing: 2026-02-19
Pipeline (4 active programs)
XPHOZAH
tenapanor Small Molecule Target: NHE3
RDX10531
Small Molecule Target: NHE3
- Undisclosed indication
Biotech Distilled coverage (2)
- 2026-07-02 UPDATE: Ardelyx (ARDX) - $50M Debt Draw, No Dilution
- 2026-07-01 Ardelyx (ARDX) — Scientific Deep Dive for IBSRELA, XPHOZAH, and the Tenapanor Pipeline
Articles open on Substack. Some deep dives are subscriber-only.